Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2023)

Silence Therapeutics (SLN) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $73.2 million as the latest value for Q4 2023.

  • Quarterly Total Non-Current Liabilities fell 1.65% to $73.2 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $73.2 million through Dec 2023, down 1.65% year-over-year, with the annual reading at $73.2 million for FY2023, 6.79% down from the prior year.
  • Total Non-Current Liabilities hit $73.2 million in Q4 2023 for Silence Therapeutics, down from $74.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $97.7 million in Q4 2021 to a low of $19.9 million in Q4 2019.
  • Historically, Total Non-Current Liabilities has averaged $66.6 million across 5 years, with a median of $73.2 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 239.82% in 2020 and later dropped 23.81% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $19.9 million in 2019, then soared by 239.82% to $67.8 million in 2020, then soared by 44.17% to $97.7 million in 2021, then fell by 23.81% to $74.5 million in 2022, then fell by 1.65% to $73.2 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for SLN at $73.2 million in Q4 2023, $74.5 million in Q4 2022, and $97.7 million in Q4 2021.